Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Common Equity: 2017-2025

Historic Common Equity for Arcus Biosciences (RCUS) over the last 8 years, with Sep 2025 value amounting to $436.0 million.

  • Arcus Biosciences' Common Equity fell 22.83% to $436.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $436.0 million, marking a year-over-year decrease of 22.83%. This contributed to the annual value of $485.0 million for FY2024, which is 4.98% up from last year.
  • As of Q3 2025, Arcus Biosciences' Common Equity stood at $436.0 million, which was down 20.58% from $549.0 million recorded in Q2 2025.
  • Over the past 5 years, Arcus Biosciences' Common Equity peaked at $842.0 million during Q4 2021, and registered a low of $436.0 million during Q3 2025.
  • For the 3-year period, Arcus Biosciences' Common Equity averaged around $550.5 million, with its median value being $549.0 million (2025).
  • Per our database at Business Quant, Arcus Biosciences' Common Equity spiked by 372.70% in 2021 and then decreased by 29.68% in 2023.
  • Arcus Biosciences' Common Equity (Quarterly) stood at $842.0 million in 2021, then declined by 21.97% to $657.0 million in 2022, then dropped by 29.68% to $462.0 million in 2023, then rose by 4.98% to $485.0 million in 2024, then declined by 22.83% to $436.0 million in 2025.
  • Its last three reported values are $436.0 million in Q3 2025, $549.0 million for Q2 2025, and $531.0 million during Q1 2025.